Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Hims & Hers Health, Inc. or Immunocore Holdings plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Hims & Hers Health, Inc. and Immunocore Holdings plc compare based on key financial metrics to determine which better meets your investment needs.

About Hims & Hers Health, Inc. and Immunocore Holdings plc

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest Health Care Providers & Services and Hims & Hers Health, Inc., Immunocore Holdings plc Stock News

As of July 31, 2026, Hims & Hers Health, Inc. had a $6.4 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Hims & Hers Health, Inc.’s stock is down 14.5% in 2026, down 1.1% in the previous five trading days and down 57.62% in the past year.

Currently, Hims & Hers Health, Inc. does not have a price-earnings ratio. Hims & Hers Health, Inc.’s trailing 12-month revenue is $2.4 billion with a -0.6% net profit margin. Year-over-year quarterly sales growth most recently was 3.8%. Analysts expect adjusted earnings to reach $-0.500 per share for the current fiscal year. Hims & Hers Health, Inc. does not currently pay a dividend.

As of July 31, 2026, Immunocore Holdings plc had a $1.7 billion market cap, putting it in the 52nd percentile of all stocks. Immunocore Holdings plc’s stock is down 2.6% in 2026, down 3.4% in the previous five trading days and up 0.93% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $412.8 million with a -6.7% net profit margin. Year-over-year quarterly sales growth most recently was 13.6%. Analysts expect adjusted earnings to reach $0.134 per share for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

How We Compare Hims & Hers Health, Inc. and Immunocore Holdings plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Hims & Hers Health, Inc. and Immunocore Holdings plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Hims & Hers Health, Inc. and Immunocore Holdings plc Growth Grades

Company	Ticker	Growth
Hims & Hers Health, Inc.	HIMS	D
Immunocore Holdings plc	IMCR	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Hims & Hers Health, Inc. has a Growth Score of 37, which is Weak. Immunocore Holdings plc has a Growth Score of 26, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Immunocore Holdings plc has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Immunocore Holdings plc is the better investment when it comes to sustainable growth.

Hims & Hers Health, Inc. and Immunocore Holdings plc’s Quality Grades

Company	Ticker	Quality
Hims & Hers Health, Inc.	HIMS	C
Immunocore Holdings plc	IMCR	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Hims & Hers Health, Inc. has a Quality Score of 43, which is Average. Immunocore Holdings plc has a Quality Score of 29, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Immunocore Holdings plc has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Immunocore Holdings plc is the better investment when it comes to quality.

Hims & Hers Health, Inc. and Immunocore Holdings plc’s Momentum Grades

Company	Ticker	Momentum
Hims & Hers Health, Inc.	HIMS	F
Immunocore Holdings plc	IMCR	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Hims & Hers Health, Inc. has a Momentum Score of 15, which is Very Weak. Immunocore Holdings plc has a Momentum Score of 57, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Immunocore Holdings plc has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Immunocore Holdings plc is the better investment when it comes to momentum.

Other Hims & Hers Health, Inc. and Immunocore Holdings plc Grades

In addition to Quality, Momentum and Growth, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Hims & Hers Health, Inc. and Immunocore Holdings plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Hims & Hers Health, Inc. or Immunocore Holdings plc Stock?

Overall, Hims & Hers Health, Inc. stock has a Growth Score of 37, Momentum Score of 15 and Quality Score of 43.

Immunocore Holdings plc stock has a Growth Score of 26, Momentum Score of 57 and Quality Score of 29.

Comparing Hims & Hers Health, Inc. and Immunocore Holdings plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.